Interaction Checker

Interaksi Ifosfamid

Ifosfamid (Ifex) memiliki 83 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 1 mayor, 76 moderat, 6 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (1)

  • MesnaMayor

    Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna [see Warnings and Precautions (5.3) ] . (label Ifosfamid, Peringatan kotak hitam)

Interaksi moderat (76)

  • AlkoholAlkoholModerat

    Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use. (label Ifosfamid, Peringatan dan perhatian)

  • AmiodaronantiaritmiaModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Moderat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Artikain dan epinefrinanestetik lokalModerat

    …anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium… (label Artikain dan epinefrin, Interaksi obat)

  • AtazanavirantiretroviralModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Bupivakain dan epinefrinanestetik lokalModerat

    …anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium… (label Bupivakain dan epinefrin, Interaksi obat)

  • BusulfanModerat

    Hemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment. (label Ifosfamid, Peringatan dan perhatian)

  • DarunavirantiretroviralModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Deferasirokssuplemen zat besiModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • DeksametasonkortikosteroidModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • DronedaronantiaritmiaModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • EfavirenzantiretroviralModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Eritromisinantibiotik makrolidaModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • EslikarbazepinantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • EtravirinantiretroviralModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • EverolimusimunosupresanModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • FenitoinantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • FenobarbitalbarbituratModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Flukonazolantijamur azolModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • FosamprenavirantiretroviralModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • FosfenitoinantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • GriseofulvinantijamurModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Imatinibpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • IsoniazidantibiotikModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Itrakonazolantijamur azolModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • KarbamazepinantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Ketokonazolantijamur azolModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Klaritromisinantibiotik makrolidaModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • KlobazambenzodiazepinModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Kloroprokainanestetik lokalModerat

    …anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium… (label Kloroprokain, Perhatian)

  • LenakapavirantiretroviralModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Mepivakainanestetik lokalModerat

    …anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium… (label Mepivakain, Interaksi obat)

  • Metilen birupenghambat MAOModerat

    Consider methylene blue for treatment of encephalopathy. (label Ifosfamid, Peringatan dan perhatian)

  • Mifepristonpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Mirabegronagonis beta-adrenergikModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Modafinilstimulan SSPModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Nafsilinantibiotik penisilinModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • NefazodonantidepresanModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • NevirapinantiretroviralModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • OkskarbazepinantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • PerampanelantikonvulsanModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Posakonazolantijamur azolModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Prilokain dan epinefrinanestetik lokalModerat

    …anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic Agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium… (label Prilokain dan epinefrin, Interaksi obat)

  • PrimidonantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • RifabutinantibiotikModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • RifampisinantibiotikModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • RifapentinantibiotikModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • RitonavirantiretroviralModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • Ropivakainanestetik lokalModerat

    …anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium… (label Ropivakain, Interaksi obat)

  • SenobamatantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • SiklosporinimunosupresanModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Simetidinpenghambat H2Moderat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • SisplatinModerat

    Risk factors include high ifosfamide dosage, hypoalbuminemia, impaired renal function, poor performance status, bulky abdominal-pelvic disease, nephrotoxic treatments including cisplatin, CNS active drugs, or alcohol use. (label Ifosfamid, Peringatan dan perhatian)

  • Suvoreksantsedatif-hipnotikModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Moderat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • TikagrelorantiplateletModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • TopiramatantikonvulsanModerat

    • CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (label Ifosfamid, Interaksi obat)

  • VasopresinModerat

    Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (label Vasopresin, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

  • Vorikonazolantijamur azolModerat

    • CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide. (label Ifosfamid, Interaksi obat)

Penyebutan minor (6)

  • Levotiroksinhormon tiroidMinor

    Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (label Ifosfamid, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidMinor

    Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (label Ifosfamid, Peringatan dan perhatian)

  • Liotironinhormon tiroidMinor

    Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (label Ifosfamid, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidMinor

    Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (label Ifosfamid, Peringatan dan perhatian)

  • Teriparatidhormon tiroidMinor

    Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (label Ifosfamid, Peringatan dan perhatian)

  • Tiamazolobat antitiroidMinor

    Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (label Ifosfamid, Peringatan dan perhatian)

Periksa Ifosfamid terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.